Baidu
map

遗传学大牛Nature Methods发表新成果 用CRISPR打造DNA条码

2016-12-09 生物通/叶予 生物通/叶予

细菌一直在与病毒或入侵核酸进行斗争,为此它们演化出了多种防御机制,CRISPR–Cas9适应性免疫系统就是其中之一。规律成簇的间隔短回文重复CRISPR与内切酶Cas9的组合,可以在引导RNA的指引下,靶标并切割入侵者的遗传物质。2012年研究者们利用这一特点,将CRISPR系统制成了强大的基因组编辑工具。哈佛医学院和加州大学的研究人员最近在CRISPR–Cas9的基础上,开发了在活细胞中快速演化


细菌一直在与病毒或入侵核酸进行斗争,为此它们演化出了多种防御机制,CRISPR–Cas9适应性免疫系统就是其中之一。规律成簇的间隔短回文重复CRISPR与内切酶Cas9的组合,可以在引导RNA的指引下,靶标并切割入侵者的遗传物质。2012年研究者们利用这一特点,将CRISPR系统制成了强大的基因组编辑工具。

哈佛医学院和加州大学的研究人员最近在CRISPR–Cas9的基础上,开发了在活细胞中快速演化的DNA条码。这项研究发表在Nature Methods杂志上,文章通讯作者是哈佛医学院的著名遗传学家George M Church和加州大学圣地亚哥分校的Prashant Mali。

George M Church是哈佛医学院的遗传学教授、Wyss研究所的核心成员。他开发了首个直接基因组测序和DNA多重化方法,为1994年破译首个细菌基因组合2003年的二代测序技术奠定基础。他领导个人基因组项目,让公众参与进来分享基因组和健康数据。他想办法用DNA编码数据,暂时记录了活细胞中的事件。他将基因组读写技术结合起来,对细菌基因组进行迄今最大规模的重写。他还率先将CRISPR用于器官移植、逆转衰老和gene drive。

研究人员构建了一种归巢引导RNA(hgRNA)。这种hgRNA会指导Cas9–hgRNA复合体到hgRNA自己的DNA位点。研究显示,归巢CRISPR–Cas9系统可以作为细胞内表达的基因编码,以可控的速度在体外培养的细胞中发生序列多样化。

随后,研究人员在细胞群体中进一步评估这些条码。他们的研究表明,归巢CRISPR条码可以用来记录谱系历史,而且条码RNA能够原位扩增,符合原位测序的先决条件。研究人员指出,这个方法有广泛的应用前景,比如深度谱系示踪、细胞条码、分子条码,可用来分析癌症生物学机制和连接组(connectome)图谱。

原始出处

Reza Kalhor, Prashant Mali & George M Church.Rapidly evolving homing CRISPR barcodes.NATURE METHODS.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881491, encodeId=714018814912a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 06 07:08:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922171, encodeId=61f519221e126, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Sep 26 00:08:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843907, encodeId=001a184390e83, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Mar 02 05:08:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895980, encodeId=face189598081, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 04 03:08:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275956, encodeId=bade12e595653, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Dec 11 01:08:00 CST 2016, time=2016-12-11, status=1, ipAttribution=)]
    2017-07-06 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881491, encodeId=714018814912a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 06 07:08:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922171, encodeId=61f519221e126, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Sep 26 00:08:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843907, encodeId=001a184390e83, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Mar 02 05:08:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895980, encodeId=face189598081, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 04 03:08:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275956, encodeId=bade12e595653, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Dec 11 01:08:00 CST 2016, time=2016-12-11, status=1, ipAttribution=)]
    2017-09-26 wgx306
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881491, encodeId=714018814912a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 06 07:08:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922171, encodeId=61f519221e126, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Sep 26 00:08:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843907, encodeId=001a184390e83, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Mar 02 05:08:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895980, encodeId=face189598081, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 04 03:08:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275956, encodeId=bade12e595653, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Dec 11 01:08:00 CST 2016, time=2016-12-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881491, encodeId=714018814912a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 06 07:08:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922171, encodeId=61f519221e126, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Sep 26 00:08:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843907, encodeId=001a184390e83, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Mar 02 05:08:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895980, encodeId=face189598081, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 04 03:08:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275956, encodeId=bade12e595653, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Dec 11 01:08:00 CST 2016, time=2016-12-11, status=1, ipAttribution=)]
    2017-08-04 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881491, encodeId=714018814912a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 06 07:08:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922171, encodeId=61f519221e126, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Sep 26 00:08:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843907, encodeId=001a184390e83, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Mar 02 05:08:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895980, encodeId=face189598081, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 04 03:08:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275956, encodeId=bade12e595653, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Dec 11 01:08:00 CST 2016, time=2016-12-11, status=1, ipAttribution=)]
    2016-12-11 yuandd

相关资讯

Nature:CRISPR治疗镰刀形细胞贫血症临床前试验成功

斯坦福大学医学院的研究团队利用CRISPR技术,在人体干细胞中修复了造成镰状细胞贫血病的基因,这些干细胞可以正常移植到小鼠体内并蓬勃发育。关于这项临床前试验成功的研究文章于11月7日在线发表在Nature上。

哈佛“大神”全新Cell:“魔剪”CRISPR为何越来越“牛”?

上周,“中国进行全球首个基于CRISPR的临床试验”、“CRISPR首次实现可任意编辑非分裂细胞”两条新闻让这一颠覆性的技术再次备受瞩目。今天,小编要为大家介绍一篇最新发表在Cell杂志上的CRISPR综述,带大家了解这一技术的修炼升级过程。这一文章的通讯作者是该领域的一位“大神”——David R. Liu。David R. Liu现为哈佛大学化学与化学生物学教授、Howard Hughes

张锋再发CRISPR新突破!“魔剪”可实现同时编辑4个基因

导语:张锋“大神”本周又在Nature Biotechnology上发表了一项CRISPR突破成果。研究描述了一种可实现同时编辑4个基因的系统。这一名为CRISPR/Cpf1的系统最早由张锋研究组于去年9月发表在Cell上的一篇论文中提出。截至目前,包括CRISPR“女神”Emmanuelle Charpentier在内的科学家们已经发表了多篇与CRISPR/Cpf1系统相关的重要成果。12月5日

Cell子刊:CRISPR直击HIV感染的预防和治愈

CRISPR是最近备受推崇的基因组编辑技术,它能够高效而精准地编辑基因组中几乎所有的序列,这将大大促进疾病研究和新疗法开发。著名科学期刊《Cell Reports》日前发布了一项新成果,科学家利用CRISPR/Cas9基因编辑系统,在人体免疫T细胞内对45个与HIV入侵宿主相关的基因进行特殊编辑分析,甄别出了其中某些基因经编辑改造发生突变后,可保护T细胞免受HIV病毒的侵入、整合、转染。这对于彻底

从魔剪到六脉神剑,CRISPR多重编辑时代到来?

2015年,《科学》杂志把CRISPR-Cas9基因编辑技术评为最重要的“突破性发现”,众多科学家普遍认为CRISPR/Cas9是上个世纪70年代生物技术(biotechnology)时代以来出现的最为重要的基因工程技术之一。▲CRISPR-Cas9系统是微生物对付外来DNA的防御系统之一(图片来源:Wikipedia)其实,CRISPR-Cas9系统只是进化过程中细菌微生物演化出的一种对付外

CRISPR新技术!神奇的“剪刀”:可用于任何细胞类型

日前,发表在Development 上题为“Optimized inducible shRNA and CRISPR/Cas9 platforms for in vitro studies of human development using hPSCs”的一项研究中,Wellcome Trust Sanger 研究所和剑桥大学的科学家们创造了一种更高效、可控的CRISPR基因组编辑平台——sOP

Baidu
map
Baidu
map
Baidu
map